The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | PACE-LUNG: osimertinib and ctDNA-guided chemotherapy intensification in EGFRm NSCLC
Martin Sebastian, MD, Goethe University Frankfurt, Frankfurt am Main, Germany, discusses results from the Phase II PACE-LUNG trial (EudraCT 2019-004757-88), which evaluated adding chemotherapy to osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had persistent circulating tumor DNA EGFR mutation positivity after three weeks of first-line osimertinib. This biomarker-guided intensification strategy was feasible, with progression-free survival comparing favorably with historical data and no new safety signals. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
